Adaptivity on the rise at Lilly; Mayo Clinic to tap EHRs for trial recruitment;

> Adaptive trials appear to be gaining traction: Eli Lilly is using an adaptive design for studies of a diabetes drug candidate. I-SPY2 studies biomarkers to see if they can point to the breast cancer patients most likely to benefit from different drugs made by Abbott, Amgen and Pfizer. Article

> The Mayo Clinic is working to unlock data in 7 million patient electronic health records to accelerate clinical trial recruitment. Article

> Contract researcher Health Decisions, a proponent of adaptive trial design, has signed with OmniComm for the TrialMaster electronic data capture platform. Announcement

> Philadelphia-based ePharmaSolutions is collaborating with iTrials to integrate the latter's HIPAA-compliant longitudinal patient database, which links 80 million patients with 350,000 physicians, into ePharmaSolutions' Clinical Research Investigator Database. Release

> Oracle has launched Argus Safety Japan 6.0, a pharmacovigilance solution for Japanese health sciences organizations and global companies serving Japan. Release

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.